Wednesday 7 October

11.00–11.05Welcome to HIV Glasgow Day Three

11.05–11.35The Joep Lange and Jacqueline van Tongeren Memorial Lecture:
PrEP in Practice

Jean-Michel Molina, Infectious Diseases Department, Saint-Louis and Lariboisière
Hospitals, and University of Paris, Paris, France
Lecture dedicated to Joep Lange and Jacqueline van Tongeren in recognition of
their commitment and passion to rid the world of HIV/AIDS

Introduction by: Linda-Gail Bekker

11.35–12.00Panel Discussion and Q & A
Jean-Michel Molina joined by Linda-Gail Bekker and Ann Sullivan, HIV and
Genito-urinary Medicine, Chelsea and Westminster Hospital NHS Foundation
Trust, and Imperial College, London, UK

12.00–12.15Break

12.15–12.45Key questions in WLWHIV and ageing: menopause and frailty
management in clinical practice

In collaboration with the European AIDS Clinical Society (EACS) and Women Against
Viruses in Europe (WAVE)

Chair:María Jesús Pérez Elías, HIV Unit, Infectious Diseases Department,
Hospital Ramón y Cajal, Madrid, Spain

12.15–12.25Key questions in WLWHIV and ageing: menopause
Fátima Brañas, Geriatric Department, Hospital Infanta Leonor, Madrid, Spain

12.25–12.35Key questions in WLWHIV and ageing: frailty
Matilde Sánchez Conde
, Infectious Diseases Department, Hospital
Ramón y Cajal, Madrid, Spain

12.35–12.45Q & A

12.45–13.15Break

13.15–14.30Industry Symposium

14.30–15.00Break

15.00–15.45Lock Lecture

15.00–15.05Lock Lecture: introduction

15.05–15.35Lock Lecture: Managing costs while delivering state-of-the-art HIV care
and prevention
Rochelle Walensky, 
Boston, MA, USA

15.35–15.45Q & A

15.45–16.00Break

16.00–17.00HIV and Resistance

16.00–16.15Do we need to worry about ART drug resistance anymore?
Huldrych Günthard, Zurich, Switzerland

16.15–16.23Integrase-based first-line HIV antiretroviral treatment in the Mediterranean
Resistance (MeditRes) HIV collaboration
Federico Garcia,
Granada, Spain

16.23–16.31Impact of multi-drug resistance on mortality: a multi-cohort Italian study
Roberta Gagliardini, Rome, Italy

16.31–16.39Lenacapavir resistance analysis in a phase Ib clinical proof-of-concept study
Nicolas Margot, Clinical Virology, Gilead Sciences, Inc., Foster City, CA, USA

16.39–17.00Q & A

17.00–17.15Break

17.15–18.15Interactive Case Study Session
In collaboration with the University of Liverpool Drug Interaction Team

Chair: Saye Khoo, University of Liverpool, Liverpool, UK

17.15–17.30Case 1: A 2020 vision of DDIs
Marta Boffito, London, UK

17.30–17.45Case 2:. The ‘ibs’ and ‘abs’ of cancer
Alessia Dalla Pria, London, UK

17.45–18.00Case 3: When options run out
Saye Khoo

18.00–12.15Q&A